Upcoming Event: Delivering Genomic Medicine

From the event page: “Since the FDA shut down 23andMe’s health related products late last year, a separation has grown in the genomics community between those who think 23andMe is good for personalized medicine, and those who think the DTC company has been harmful. The former argue that 23andMe has simplified genomics for the masses through their marketing and PR campaigns and through their online reports. Those opposed warn that the data and the reports are over simplified.

When talking about how to understand, interpret, and report genomic data, one of the challenges is presenting to various levels of users. There are the patients–or consumers as some like to say, the doctors, lab techs, and, of course, other researchers. The secret behind translating research into better clinical outcomes depends not just on Big Data, but how it looks.”